Literature DB >> 26766969

Correlation study and significance of the EGFR expression in serum, lymph nodes and tumor tissue of NSCLC.

Yinling Zhuo1, Qisen Guo2, Pingping Song3, Qiong Zhang4, Chen Guo5, Hongsheng Zeng6, Yan Guan2, Xiuju Liu2, Chenqing Zhao7.   

Abstract

BACKGROUND: This study was designed to detect the protein expression of epidermal growth factor receptor (EGFR) among serum, lymph node, and tumor tissues, and to discuss their relationship and clinical significance. We investigated whether EGFR levels in serum and lymph nodes could be used as an effective method for non-small cell lung cancer (NSCLC) to diagnose and assess clinical stage.
METHODS: In 56 patients with NSCLC and 10 individuals with nonmalignant thoracic disease, we measured EGFR levels in serum using an enzyme immunoassay, and EGFR mRNA levels in lymph node and NSCLC tissues by quantitative real-time-polymerase chain reaction. We examined the correlation between them and with the clinical parameters.
RESULTS: Serum EGFR levels substantially decreased after surgical treatment (P < 0.001). Serum EGFR levels were correlated with smoking, surgery, and pathological type after surgery (all P < 0.05). EGFR mRNA levels in lymph node and tumor tissues were correlated more closely with lymph node metastasis (P = 0.015. EGFR mRNA in tissues was higher than that of benign pulmonary diseases (P = 0.020). There was an obvious positive correlation among EGFR levels of serum and lymph node tissues (r = 0.764; P < 0.001), serum and tumor tissues (r = 0.616; P < 0.001), and lymph node and tumor tissues (r = 0.904; P < 0.001) in NSCLCs.
CONCLUSION: The data suggest that detecting EGFR levels in serum and lymph node tissues could be a simple and effective method to diagnose and assess the clinical stage in patients with NSCLC.

Entities:  

Keywords:  EGFR; enzyme-linked immunosorbent assay; lung neoplasms; polymerase chain reaction

Year:  2014        PMID: 26766969      PMCID: PMC4704271          DOI: 10.1111/1759-7714.12048

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  27 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Treatment of advanced non-small cell lung cancer.

Authors:  Heine H Hansen
Journal:  BMJ       Date:  2002-08-31

3.  Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer.

Authors:  Norimasa Miura; Hiroshige Nakamura; Reina Sato; Tomoe Tsukamoto; Tomomi Harada; Shunsaku Takahashi; Youshin Adachi; Kohei Shomori; Akiko Sano; Yosuke Kishimoto; Hisao Ito; Junichi Hasegawa; Goshi Shiota
Journal:  Cancer Sci       Date:  2006-12       Impact factor: 6.716

Review 4.  The nuclear epidermal growth factor receptor signaling network and its role in cancer.

Authors:  Toni M Brand; Mari Iida; Chunrong Li; Deric L Wheeler
Journal:  Discov Med       Date:  2011-11       Impact factor: 2.970

5.  Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer.

Authors:  T Berghmans; A P Meert; B Martin; V Ninane; J P Sculier
Journal:  Eur Respir J       Date:  2005-02       Impact factor: 16.671

Review 6.  Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy.

Authors:  E Raymond; S Faivre; J P Armand
Journal:  Drugs       Date:  2000       Impact factor: 9.546

7.  Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.

Authors:  Binaifer R Balsara; Jianming Pei; Yasuhiro Mitsuuchi; Robert Page; Andres Klein-Szanto; Hao Wang; Michael Unger; Joseph R Testa
Journal:  Carcinogenesis       Date:  2004-07-07       Impact factor: 4.944

Review 8.  Targeting the epidermal growth factor receptor in non-small cell lung cancer.

Authors:  Roy S Herbst; Paul A Bunn
Journal:  Clin Cancer Res       Date:  2003-12-01       Impact factor: 12.531

9.  Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.

Authors:  Carlos Gomez-Roca; Christophe M Raynaud; Frederique Penault-Llorca; Olaf Mercier; Frederic Commo; Luc Morat; Laure Sabatier; Philipe Dartevelle; Estelle Taranchon; Benjamin Besse; Pierre Validire; Antoine Italiano; Jean-Charles Soria
Journal:  J Thorac Oncol       Date:  2009-10       Impact factor: 15.609

10.  Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.

Authors:  Ivan Milas; Ritsuko Komaki; Tsutomu Hachiya; Robbin S Bubb; Jae Y Ro; Lauren Langford; Raymond Sawaya; Joe B Putnam; Pamela Allen; James D Cox; Timothy J McDonnell; William Brock; Waun Ki Hong; Jack A Roth; Luka Milas
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531

View more
  3 in total

Review 1.  Role of cytokines in combinatorial immunotherapeutics of non-small cell lung cancer through systems perspective.

Authors:  Pragya Misra; Shailza Singh
Journal:  Cancer Med       Date:  2019-04-17       Impact factor: 4.452

2.  Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients.

Authors:  Ruirui Jiang; Bo Zhang; Xiaodong Teng; Peizhen Hu; Sanpeng Xu; Zuyu Zheng; Rui Liu; Tingdong Tang; Feng Ye
Journal:  Sci Rep       Date:  2020-02-07       Impact factor: 4.379

3.  Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer.

Authors:  Anant Mohan; Ashraf Ansari; Mirza Masroor; Alpana Saxena; R M Pandey; Ashish Upadhyay; Kalpana Luthra; G C Khilnani; Deepali Jain; Rakesh Kumar; Randeep Guleria
Journal:  Asian Pac J Cancer Prev       Date:  2020-11-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.